The International Subarachnoid Aneurysm Trial (ISAT) is a well organized clinical trial, but there are several criticisms of its study design and selection bias of enrolled patients. Published guidelines on the management of ruptured intracranial aneurysms and current treatment tendencies are reviewed in order to consider the impact of ISAT on the appropriate selection of treatment modality.
